<DOC>
	<DOCNO>NCT00662857</DOCNO>
	<brief_summary>28 subject enrol screening period , 3 dose visit &amp; follow-up visit . Visits 2 3 dose TI Inhalation Powder , cross two 15 U cartridge one 30 U cartridge . Visit 4 dose sc injection 10 IU RAA ( rapid-acting insulin analogue ) .</brief_summary>
	<brief_title>A Study Designed Compare 2 Dose Strengths TI Inhalation Powder Adults With Type 1 Diabetes Mellitus Compare One Those Formulations ( 30Units ) With Injection Insulin Lispro</brief_title>
	<detailed_description>28 eligible subject plan enrolled determine bioequivalence safety parameter two 15 U TI Inhalation Powder cartridges versus one 30 U TI Inhalation Powder cartridge , accord randomize , 2-way crossover design . Additionally , bioavailability one 30 U TI Inhalation Powder cartridge single subcutaneous injection 10 IU RAA compare .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Males Females &gt; 18 &lt; 60 year age Clinical diagnosis type 1 diabetes mellitus stable antidiabetic regimen least 90 day prior Screening BMI &lt; 30 kg/m2 Nonsmokers ( never smoke former smoker ( &gt; 6 month since cessation ) Pulmonary Function Testing ( FEV1 &gt; 70 % , FEV1/FVC &gt; 70 % , TLC &gt; 80 % DLco [ unc ] &gt; 70 % Predicted Written Informed consent Two severe hypoglycemic episode within 6 month Screening/Visit 1 Severe complication diabetes Previous exposure inhale insulin product TI inhalation Powder similar formulation Inability perform PFT maneuver meet recommended American Thoracic Society ( ATS ) standard acceptability repeatability criterion Respiratory tract infection within 8 week prior Screening/Visit 1 History chronic obstructive pulmonary disease ( COPD ) , clinically proven asthma , and/or clinically important pulmonary disease ( eg . Obstructive sleep apnea ) , confirm pulmonary function testing , and/or radiologic finding Major organ system diseases include seizure , heart failure , uncontrolled hypertension , cancer within past 5 year , liver disease , anemia autoimmune disorder Clinically significant abnormality screen laboratory evaluation Female subject pregnant , lactating , plan become pregnant clinical trial period practice adequate birth control Unable and/or unlikely comprehend use investigational device study follow study instruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Diabetic adult male , diabetic adult female</keyword>
</DOC>